Key statistics
On Friday, Esperion Therapeutics Inc (0IIM:LSE) closed at 3.29, -21.10% below its 52-week high of 4.17, set on Jan 08, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 3.29 |
| Low | 3.29 |
| Bid | -- |
| Offer | -- |
| Previous close | 3.29 |
| Average volume | 23.62k |
|---|---|
| Shares outstanding | 239.06m |
| Free float | 237.55m |
| P/E (TTM) | -- |
| Market cap | 800.86m USD |
| EPS (TTM) | -0.5358 USD |
Data delayed at least 20 minutes, as of Feb 27 2026 17:20 GMT.
More ▼
Announcements
- Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10
- Esperion to Participate in The 2026 Citizens Life Sciences Conference
- Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
- Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
- Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
- Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
More ▼
